• 1. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 4. Always a matter of interpretation: inferring student knowledge and understanding from research data
  Chem. Educ. Res. Pract., 2017,18, 7-12
• 5. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles Aminothiazoles

4,4-Dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine: A Comprehensive Overview

CAS No. 1182284-47-4, also known as 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine, is a unique and intriguing compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of thiazoles, which are heterocyclic compounds characterized by a five-membered ring containing one sulfur and one nitrogen atom. The presence of the dimethyl substituents and the cyclopentane ring system imparts distinct structural and chemical properties to this molecule.

The structural features of 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine are crucial for its biological activity. The thiazole ring is known for its ability to form hydrogen bonds and participate in π-stacking interactions, which are essential for binding to biological targets. The dimethyl substituents on the cyclopentane ring enhance the lipophilicity of the molecule, potentially improving its membrane permeability and bioavailability. These properties make it an attractive candidate for drug development.

Recent research studies have explored the potential applications of 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine in various therapeutic areas. One notable area of interest is its antimicrobial activity. Thiazoles are well-known for their broad-spectrum antimicrobial properties, and preliminary studies have shown that 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine exhibits potent activity against both Gram-positive and Gram-negative bacteria. This makes it a promising lead compound for the development of new antibiotics to combat drug-resistant bacterial infections.

In addition to its antimicrobial properties, 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine has also been investigated for its anti-inflammatory effects. Inflammatory diseases such as arthritis and inflammatory bowel disease (IBD) are characterized by chronic inflammation and tissue damage. Studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro. These findings suggest that 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine may have therapeutic potential in managing inflammatory conditions.

Another area of interest is the neuroprotective properties of 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease are characterized by the progressive loss of neurons and cognitive decline. Research has shown that this compound can protect neurons from oxidative stress and reduce neuroinflammation in animal models. These neuroprotective effects make it a potential candidate for the treatment of neurodegenerative disorders.

The pharmacokinetic properties of 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine have also been studied to assess its suitability as a therapeutic agent. Preclinical studies have demonstrated that this compound has good oral bioavailability and a favorable pharmacokinetic profile. It exhibits low plasma protein binding and is metabolized primarily through hepatic pathways. These characteristics suggest that it can be effectively absorbed and distributed in the body after oral administration.

Furthermore, toxicity studies have been conducted to evaluate the safety profile of 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine. In vitro assays using human cell lines have shown that it has low cytotoxicity at therapeutic concentrations. Animal studies have also indicated that it is well-tolerated at higher doses without significant adverse effects on major organs such as the liver and kidneys. These findings support its potential for further clinical development.

In conclusion, 4,4-dimethyl-4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine (CAS No. 1182284-47-4) is a promising compound with a diverse range of biological activities. Its unique structural features contribute to its antimicrobial, anti-inflammatory, and neuroprotective properties. Ongoing research continues to explore its therapeutic potential in various diseases and conditions. As more data becomes available from preclinical and clinical studies, this compound may emerge as a valuable addition to the arsenal of drugs used in modern medicine.

• 58482-94-3(2-BENZOTHIAZOLAMINE, 4,5,6,7-TETRAHYDRO-5,7-DIMETHYL-)
• 867285-14-1(4,4-dimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine)
• 188051-12-9(Spiro[benzothiazole-6(5H),1'-cyclohexan]-2-amine, 4,7-dihydro-)
• 27460-91-9(2-Benzothiazolamine, 4,5,6,7-tetrahydro-5,5,7-trimethyl-)
• 81779-11-5(2-Amino-6-tert-butyl-4,5,6,7-tetrahydrobenzothiazole)
• 7496-50-6(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine)
• 867285-07-2(6-ethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine)
• 53051-97-1(4H,5H,6H-cyclopenta[d][1,3]thiazol-2-amine)
• 72029-36-8((1r,3as,3br,5as,10as,10bs,12ar)-10a,12a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-1h-cyclopenta[7,8]phenanthro[2,3-d][1,3]thiazol-8-amine)
• 867286-03-1(2-BENZOTHIAZOLAMINE, 4,5,6,7-TETRAHYDRO-6-PENTYL-)